Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
PLN 890
Key Takeaways
Risk factor
Poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very strong margins and returns
Data is available to registered users only
Data is available to registered users only
About
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular diseases; the gastrointestinal tract; central nervous system; pain relief; anti-infectives; blood and blood-forming...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair
Data is available to registered users only
